SueWallSt

In this episode of Sue Wall Street, we unpack what happens when company execs treat fiduciary duties like a suggestion not a requirement. From insider enrichment to reckless decisions masked as “business judgment,” we break down how shareholders get burned and how class actions try to restore accountability. If you’ve ever owned stock or trusted a CEO, this one’s for you. Great for retail investors, governance nerds, and legal-watchers.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

In this episode of Sue Wall Street, Cassie and Bill dive into the spectacular collapse of $ANRO Alto Neuroscience. After raising $119M in its 2024 IPO on hopes of revolutionizing psychiatry, its flagship drug ALTO-100 flunked a critical trial—sending shares plummeting nearly 70%. We unpack the lawsuit alleging misleading IPO documents, dig into the risks of precision medicine, and ask: was this hype or just heartbreak? Perfect for investors, biotech watchers, and anyone tracking Wall Street accountability.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

In this episode of Sue Wall Street we breakdown of how companies like $XYZ use slick summaries, cherry-picked data, and non-GAAP tricks to inflate projections and potentially deceive investors. We explore what counts as misleading, when safe harbor doesn't apply, and how class actions kick off after the truth hits. If you're an investor, analyst, or just tired of corporate spin, this one's for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

What happens when a pigment powerhouse promises shine but delivers a splatter? In this episode of Sue Wall Street, we break down the class action lawsuit against $TROX Tronox Holdings after the company hyped up bullish forecasts—then slashed guidance and dividends when the truth hit. Perfect for investors, analysts, and market watchers who want the inside scoop on flawed forecasts, chemical industry volatility, and how one earnings report triggered a 38% drop.

Visit ZLK.com for more info.

On this episode of Sue Wall Street, we dig into the DOJ’s five-year shadow investigation into $SMLR and why Semler Scientific never told investors. While hyping up compliance risks, the company failed to disclose five civil investigative demands and a looming $29.75M settlement tied to its QuantaFlo device. With shares dropping and trust eroding, this class action could reshape medical device disclosures. For retail investors, healthcare analysts, and compliance hawks.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

This week on Sue Wall Street, we unpack the wild ride behind $NUTX—from skyrocketing arbitration profits to a scathing short-seller report alleging fraud. Nutex Health's partnership with HaloMD, now under fire, may have fueled inflated revenues and shareholder deception. With missed filings, internal control failures, and a looming restatement, this class action could shake up the healthcare sector. Ideal for retail investors, healthcare analysts, and fraud sleuths.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

When a biotech darling gets FDA-snubbed, investors feel the burn. In this episode of Sue Wall Street, we dig into the class action lawsuit against $REPL Replimune after its cancer trial bombed and the FDA called it “not adequate or well-controlled.” If you're a biotech investor, trader, or market skeptic, this one’s for you. Expect sharp commentary, legal breakdowns, and eye-popping stock drops as we unpack what went wrong — and what comes next.

Visit ZLK.com for more info.

What happens when a med-tech marvel hits a legal wall? In this episode of Sue Wall Street, we unpack the class action lawsuit against $RXST RxSight Inc — the company behind light-adjustable lenses and even brighter promises. Ideal for investors, market watchers, and anyone tracking the Nasdaq's medical tech space. Expect deep dives, sharp analysis, and sharp-tongued banter as we expose how strong earnings masked hidden “adoption challenges.”

Visit ZLK.com for more info.

In this episode of Sue Wall Street, we dive into the 21% stock drop of $PUBM and the class action lawsuit shaking up PubMatic. Investors claim they were misled about key business risks, particularly a major DSP client shift that wasn’t disclosed until it was too late. If you’re an ad tech investor, shareholder, or just love watching Wall Street get called out, this one’s for you. Expect deep dives, sharp insights, and no sugarcoating.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

In this episode of Sue Wall Street we unpack the fresh class action lawsuit against $SNAP Snap Inc. Investors claim the company misled the market by hyping strong ad revenue growth while internal data showed April numbers collapsing from nine percent to just one percent. If you’re an investor, trader, or anyone tracking tech and social media stocks, this breakdown is for you. Expect sharp analysis, corporate accountability talk, and a few laughs along the way.

Visit ZLK.com for more info.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.